-+ 0.00%
-+ 0.00%
-+ 0.00%

BIOAGE ANNOUNCES INDICATION EXPANSION FOR ORAL NLRP3 INHIBITOR BGE-102, WITH PLANS TO INITIATE PHASE 1B/2A PROOF-OF-CONCEPT CLINICAL TRIAL IN PATIENTS WITH DIABETIC MACULAR EDEMA IN MID-2026

Reuters·01/20/2026 14:00:06

Please log in to view news